Compounds > sorafenib
Page last updated: 2024-09-05

sorafenib and n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide

sorafenib has been researched along with n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide in 1 studies

Compound Research Comparison

Studies
(sorafenib)		Trials
(sorafenib)		Recent Studies (post-2010)
(sorafenib)		Studies
(n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide)		Trials
(n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide)		Recent Studies (post-2010) (n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide)
6,5207305,25132032

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, F; Zhuang, C1

Reviews

1 review(s) available for sorafenib and n-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide

ArticleYear
Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.
    Journal of medicinal chemistry, 2020, 02-27, Volume: 63, Issue:4

    Topics: Animals; Cell Line, Tumor; Drug Development; Humans; Molecular Structure; Necroptosis; Protein Kinase Inhibitors; Receptor-Interacting Protein Serine-Threonine Kinases

2020